KCT0003474进行中（未招募）未知
Comparative analysis of immune profile following neoadjuvant chemotherapy in colorectal liver metastases (CRLM): A prospective pilot clinical trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •1.Have provided written informed consent prior to any study specific procedures
- •2.Willing and able to comply with the protocol
- •3.= 20 years of age at the time of signing Informed Consent Form
- •4.Eastern Cooperative Oncology Group (ECOG) status of =1
- •1.Histologically diagnosed colorectal adenocarcinoma
- •2.Liver metastases from colorectal adenocarcinoma confirmed through biopsy
- •3.Liver metastatic lesions should be considered to be potentially resectable after conversion chemotherapy by multi-disciplinary team and should meet one of the following criteria:
- •?- Number of metastatic deposit >=4
- •?- Possibility of resection margin could be involved
- •?- Involvement of major hepatic vessels
- •?- Presence of extrahepatic metastases (if they are supposed to be treated with curative aim and not to alter a plan for hepatic metastasectomy)
- •?- High likelihood of insufficient residual hepatic volume after surgery
- •4.Measurable by RECIST criteria 1.1.
- •5.One or more hepatic lesions should be accessible for biopsy
- •6.Archival tumor tissue from the metastatic liver lesion obtained at the time of the initial diagnosis must be available.
- •7.Adequate major organ functions as following:
- •?-Hematopoietic function: ANC >= 1,500/mm3, Platelet >= 100,000/mm3
- •?-Hepatic function: serum bilirubin <= 2 x ULN, AST/ALT levels <= 5 x ULN
- •?-Renal function: serum creatinine <= 1.5 x ULN
- •8.INR < 1.5 or aPTT < 1.5 x ULN within 14 days prior to the start of study treatment for patients not receiving anti-coagulation. For patients receiving anticoagulants, INR and aPTT must be within the medical standard of enrolling institution.
- •1.For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of ? 1% per year during the treatment period and for 6 months after the last dose of study treatment after the last dose of study treatment
- •i.A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- •ii.Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
- •2.For men, they must practice abstinence or condom use, and abstain from sperm donation during the treatment period and for 6 months after their last dose of study treatment.
排除标准
- •1.Extrahepatic metastases that are not candidates for treatment of curative aim (e.g. resection, radiation or radiofrequency ablation)
- •2.Presence of central nervous system (CNS) metastases
- •3.Concurrent or previous history of another primary cancer within 3 years prior to study treatment except for curatively treated cervical cancer in situ, non-melanomatous skin cancer, superficial bladder cancer (pTis or pT1) and curatively treated thyroid cancer of any stage. Concurrent, histologically confirmed, unresected thyroid cancer without distant metastasis could be allowed with the agreement of the principal investigator.
- •4.Chronic alcoholic hepatitis or cirrhosis
- •5.Chronic hepatitis B, defined as HBV DNA (> 2,000 IU / mL) and ALT> upper limit of normal range, must be treated with antiviral drugs before enrollment to reach appropriate viral suppression (HBV DNA <2000 IU / mL), and the antiviral drugs must be maintained during the study treatment period and for 6 months after the last dose of study treatment.
- •6.Prior chemotherapy for metastatic disease
- •7.Uncontrolled medical illness congestive heart failure, myocardial infarction within 6 months including medically uncontrolled infection, uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months
- •8.Prior adjuvant FOLFOX chemotherapy
- •9.Prior adjuvant chemotherapy, if administered within 6 months before study entry
- •10.Current or recent (within 10 days of start of study treatment) use of aspirin (>325mg/day), clopidogrel (>75mg/day), therapeutic or parenteral anticoagulants or thrombolytic agents for therapeutic purposes (therapeutic anticoagulation on a stable dose for at least 2 weeks prior to the start of study treatment is allowed)
- •11.Known alcohol or drug abuse
- •12.Active infection requiring intravenous antibiotics at the start of study treatment
- •13.Inadequately controlled hypertension (defined as systolic blood pressure >150mmHg and/or diastolic blood pressure >100mmHg)
- •14.Prior history of hypertensive crisis or hypertensive encephalopathy
- •15.History or evidence upon physical or neurological examination of CNS disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy
- •16.Uncontrolled chronic peripheral neuropathy = CTCAE grade 2
- •17.Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of start of study treatment
- •18.Any previous venous thromboembolism > CTCAE Grade 3 within 12 months prior to start of study treatment
- •19.History of haemoptysis = Grade 2 (defined as = 2.5 mL bright red blood per episode) within 1 month of start of study treatment
- •20.History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
- •21.Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to start of study treatment, or anticipation of need for major surgical procedure (other than hepatic metastasectomy) during the course of the study
- •22.History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to start of study treatment
- •23.Serious, non-healing wound, active ulcer, or untreated bone fracture
研究者
相似试验
尚未招募
不适用
Study of host immune response in patients of fungal infection of skin.CTRI/2019/09/021297Indian Association of Dermatologists Venereologists and Leprologists
已完成
4 期
The study to compare the immune response between intradermal and intramuscular injection of botulinum toxin AHealthy human volunteersEnzyme-Linked Immunosorbent Assay, Botulinum Toxins, Immunoglobulins, AntibodiesTCTR20211204002Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand100
已完成
Unknown
Correlation of agni and immune response in students during University examinatioCTRI/2023/09/057238DR AKANKSHA D SHIRPURKAR30
已完成
不适用
Study of immune parameters that may differ between HC and patients with MS : an explorative studyMS1000381610007951Multiple SclerosisNL-OMON37483School for Mental Health and Neuroscience100
已完成
不适用
Change in markers of immune function associated with Bacillus subtilis CU1 intervention in different age groupsNL-OMON51589Gnosis by Lesaffre90